Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint

HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that a pre-specified interim analysis assessed by the Independent Data Monitoring Committee (IDMC) of the randomized, controlled, double-blinded, …